<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590497</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-15019</org_study_id>
    <secondary_id>NCI-2015-00873</secondary_id>
    <nct_id>NCT02590497</nct_id>
  </id_info>
  <brief_title>Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery</brief_title>
  <official_title>The Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the correlation between the genetics and brain images of
      patients with newly diagnosed glioblastoma before surgery. The genetic characteristics of a
      tumor are an important way to predict how well it will respond to treatment. Imaging, using
      magnetic resonance imaging (MRI), takes detailed pictures of organs inside the body, and may
      also provide information that helps doctors predict how brain tumors will respond to
      treatment. If MRI can provide doctors with similar information about the tumor as the tumor's
      genes, it may be able to be used to predict tumor response in patients whose tumors cannot be
      reached by surgery or biopsy to get tissue samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the correlation between the genetic and neuroimaging signature of glioblastoma.

      II. Determine the correlation between the neuroimaging signature of glioblastoma and
      prognosis.

      OUTLINE:

      Patients undergo MRI before and after gadolinium contrast administration, including
      3-dimensional (3D) volumetric T1-weighted sequence, fluid attenuated inversion recovery
      (FLAIR) sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also
      analyzed for the tumor genetic profile.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI made decision
  </why_stopped>
  <start_date type="Actual">March 20, 2016</start_date>
  <completion_date type="Actual">October 26, 2017</completion_date>
  <primary_completion_date type="Actual">October 26, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the genetic and neuroimaging signature of glioblastoma and prognosis</measure>
    <time_frame>Day 1</time_frame>
    <description>The average DK parameter and CBV parameter will be compared between classes 1 and 2 based on the 9-gene expression profile at each site using two sample t-test. Data will be transformed or a nonparametric test will be conducted if necessary. Differences in DK and CBV parameters between the two MR techniques (3T MR in OSU and 1.5 T in MUSC) will be explored in each class of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusional kurtosis (DK) values</measure>
    <time_frame>Day 1</time_frame>
    <description>The average DK parameter and cerebral blood volume (CBV) parameter will be compared between classes 1 and 2 based on the 9-gene expression profile at each site using two sample t-test. Data will be transformed or a nonparametric test will be conducted if necessary. Differences in DK and CBV parameters between the two MR techniques (3T MR in Ohio State University [OSU] and 1.5 T in Medical University of South Carolina [MUSC]) will be explored in each class of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic tumor profile</measure>
    <time_frame>Day 1</time_frame>
    <description>The average DK parameter and CBV parameter will be compared between classes 1 and 2 based on the 9-gene expression profile at each site using two sample t-test. Data will be transformed or a nonparametric test will be conducted if necessary.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diffusion Weighted Imaging</intervention_name>
    <description>Undergo diffusion weighted MRI</description>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
    <other_name>Diffusion Weighted MRI</other_name>
    <other_name>Diffusion-Weighted Magnetic Resonance Imaging</other_name>
    <other_name>Diffusion-Weighted MR Imaging</other_name>
    <other_name>Diffusion-Weighted MRI</other_name>
    <other_name>DWI</other_name>
    <other_name>DWI MRI</other_name>
    <other_name>DWI-MRI</other_name>
    <other_name>MR Diffusion-Weighted Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <description>Undergo gadolinium-enhanced MRI</description>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
    <other_name>Gd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Tissue genetic analysis</description>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo gadolinium-enhanced MRI</description>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo 3D volumetric T1-weighted sequence</description>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo FLAIR sequence</description>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Perfusion Magnetic Resonance Imaging</intervention_name>
    <description>Undergo perfusion MRI</description>
    <arm_group_label>Diagnostic (MRI, tumor tissue analysis)</arm_group_label>
    <other_name>magnetic resonance perfusion imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will be undergoing surgery for newly-diagnosed glioblastoma

          -  Subtotal, gross total or biopsy patients will be eligible

          -  Confirmation of pathology as glioblastoma

        Exclusion Criteria:

          -  Tissue analysis demonstrating pathology other than glioblastoma

          -  Patients with a contraindication to having MR imaging (e.g. pacemaker) or contrast MR
             administration (e.g. hypersensitivity to gadolinium or renal insufficiency above the
             institutional threshold for administration of contrast); patients with
             hypersensitivity to MR contrast may be able to participate if it has been established
             that premedication will mitigate the hypersensitivity reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Giglio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Pierre Giglio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

